Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS3 | P29474 | 1/20 | 0.43 |
| ▸ | NOS1 | P29475 | 1/20 | 0.43 |
| ▸ | NOS2 | P35228 | 1/20 | 0.43 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.42 |
| ▸ | ADORA2A | P29274 | 11/20 | 0.41 |
| ▸ | ADORA1 | P30542 | 8/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | MAOA | P21397 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 1/20 | 0.40 |
| ▸ | IGF1R | P08069 | 1/20 | 0.39 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.39 |
| ▸ | KDR | P35968 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.37 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.37 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.37 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2082460 | 0.85 | NOS3 (0.45) | NOS3NOS1NOS2ADORA2AADORA1 | |
| SCHEMBL2261106 | 0.80 | NOS3 (0.41) | NOS3NOS1NOS2ADORA2AADORA1 | |
| SCHEMBL20840569 | 0.80 | HRH3 (0.52) | NOS3NOS1NOS2ADORA2AADORA1 | |
| SCHEMBL14025128 | 0.79 | ADRA2C (0.46) | NOS3NOS1NOS2ADORA2AADORA1 | |
| SCHEMBL27950479 | 0.78 | CYP2A6 (0.41) | CYP2A6KDM4ENPC1RAB9AIGF1R | |
| SCHEMBL21730317 | 0.78 | CYP2A6 (0.41) | CYP2A6KDM4EMAPTL3MBTL1HRH3 | |
| SCHEMBL7413041 | 0.78 | CYP2A6 (0.41) | NOS3NOS1NOS2CYP2A6KDM4E | |
| SCHEMBL2712754 | 0.78 | KDM1A (0.49) | CYP2A6ADORA2AADORA1MAOAMAOB | |
| SCHEMBL22584051 | 0.77 | ADORA2A (0.40) | NOS3NOS1NOS2ADORA2AADORA1 | |
| SCHEMBL15173994 | 0.77 | ADORA2A (0.54) | ADORA2AADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102675305-A | Imidazopyridine compounds, as well as preparation method and application thereof | SHANGHAI INST MATERIA MEDICA | 2012-09-19 | — | — | CN | claimed |
| US-12582645-B2 | Chemokine CXCR4 receptor modulators and uses related thereto | EMORY UNIVERSITY (US) | 2026-03-24 | — | — | US | disclosed |
| US-20240316034-A1 | Chemokine CXCR4 Receptor Modulators and Uses Related Thereto | UNIV EMORY (US) | 2024-09-26 | — | — | US | disclosed |
| US-20230112832-A1 | Chemokine CXCR4 Receptor Modulators and Uses Related Thereto | UNIV EMORY (US) | 2023-04-13 | — | — | US | disclosed |
| US-20230112832-A1 | Chemokine CXCR4 Receptor Modulators and Uses Related Thereto | UNIV EMORY (US) | 2023-04-13 | — | — | US | disclosed |
| US-11497744-B2 | Chemokine CXCR4 receptor modulators and uses related thereto | EMORY UNIVERSITY (US) | 2022-11-15 | — | — | US | disclosed |
| EP-3929185-A1 | NITROGEN-CONTAINING FUSED CYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (CN) | 2021-12-29 | — | — | EP | disclosed |
| EP-1613613-B1 | CXCR4 CHEMOKINE RECEPTOR BINDING COMPOUNDS | GENZYME CORP (US) | 2021-06-02 | — | — | EP | disclosed |
| EP-3478679-B1 | 5,7-DIHYDRO-PYRROLO-PYRIDINE DERIVATIVES FOR TREATING NEUROLOGICAL AND NEURODEGENERATIVE DISEASES | PFIZER (US) | 2021-04-21 | — | — | EP | disclosed |
| WO-2020102576-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS INFLAMMASOME RESEARCH, INC. (US) | 2020-05-22 | — | — | WO | disclosed |
| US-20080096955-A1 | Cis-3-(3-fluoro-4-pyrrolidin-1-ylmethyl-phenyl)-cyclobutanecaboxylic acid dimethylamide; for treatment of disorders or conditions that may be treated by antagonizing histamine-3 (H3) receptors; Alzheimer disease, mood and cognitive disorders, attention deficit hyperactive disorder, schizophrenia | PFIZER INC | 2008-04-24 | — | — | US | disclosed |
| US-20080070929-A1 | THIAZOLINE AND OXAZOLINE DERIVATIVES AND THEIR METHODS OF USE | ABBVIE INC. | 2008-03-20 | — | — | US | disclosed |
| WO-2008002956-A2 | THIAZOLINE AND OXAZOLINE DERIVATIVES AND THEIR METHODS OF USE | ABBOTT LABORATORIES (US) | 2008-01-03 | — | — | WO | disclosed |
| WO-2007049123-A1 | HISTAMINE-3 RECEPTOR ANTAGONISTS | PFIZER PRODUCTS INC. (US) | 2007-05-03 | — | — | WO | disclosed |
| US-5583122-A | TREATING DISEASES ASSOCIATED WITH ABNORMAL CALCIUM AND PHOSPHATE METABOLISM | THE PROCTER & GAMBLE COMPANY (US) | 1996-12-10 | — | — | US | disclosed |
| EP-0230068-B1 | USE OF A GEMINAL DIPHOSPHONIC ACID COMPOUND TO PREPARE A MEDICAMENT | Norwich Eaton Pharmaceuticals, Inc. (US) | 1992-07-15 | — | — | EP | disclosed |
| EP-0186405-B1 | PHARMACEUTICAL COMPOSITIONS CONTAINING GEMINAL DIPHOSPHONATES | THE PROCTER & GAMBLE COMPANY (US) | 1991-03-06 | — | — | EP | disclosed |
| US-4902679-A | TREATING BONE DISORDERS | NORWICH EATON PHARMACEUTICALS, INC. (US) | 1990-02-20 | — | — | US | disclosed |
| EP-0230068-A2 | Use of a geminal diphosphonic acid compound to prepare a medicament | Norwich Eaton Pharmaceuticals, Inc. (US) | 1987-07-29 | — | — | EP | disclosed |
| EP-0186405-A2 | Pharmaceutical compositions containing geminal diphosphonates | THE PROCTER & GAMBLE COMPANY (US) | 1986-07-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240316034-A1 | Chemokine CXCR4 Receptor Modulators and Uses Related Thereto | CXCR4, CXCL12, CXCR1 | NOS3 2540/4885NOS1 2528/4885NOS2 2663/4885 |
| US-20080096955-A1 | Cis-3-(3-fluoro-4-pyrrolidin-1-ylmethyl-phenyl)-cyclobutanecaboxylic acid dimethylamide; for treatment of disorders or conditions that may be treated by antagonizing histamine-3 (H3) receptors; Alzheimer disease, mood and cognitive disorders, attention deficit hyperactive disorder, schizophrenia | HRH3, HRH4, HRH2 | NOS3 2262/4885NOS1 3392/4885NOS2 3665/4885 |
| US-11497744-B2 | Chemokine CXCR4 receptor modulators and uses related thereto | CXCR4, CXCL12, CXCR1 | NOS3 2540/4885NOS1 2528/4885NOS2 2663/4885 |
| US-20230112832-A1 | Chemokine CXCR4 Receptor Modulators and Uses Related Thereto | CXCR4, CXCL12, CXCR1 | NOS3 2540/4885NOS1 2528/4885NOS2 2663/4885 |
| US-12582645-B2 | Chemokine CXCR4 receptor modulators and uses related thereto | CXCR4, CXCR2, CXCR1 | NOS3 2683/4885NOS1 3459/4885NOS2 2297/4885 |
| US-20080070929-A1 | THIAZOLINE AND OXAZOLINE DERIVATIVES AND THEIR METHODS OF USE | OXA1L, CYP3A7, ABAT | NOS3 1328/4885NOS1 2122/4885NOS2 1420/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.